Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 1;10(1):16362.
doi: 10.1038/s41598-020-73335-2.

Detection of urinary podocytes by flow cytometry in idiopathic membranous nephropathy

Affiliations

Detection of urinary podocytes by flow cytometry in idiopathic membranous nephropathy

Alberto Mella et al. Sci Rep. .

Erratum in

Abstract

Idiopathic membranous nephropathy (iMN) is considered an immune-mediated disease where circulating autoantibodies against podocyte targets (mainly the PLA2R) cause the deposition of in-situ subepithelial immune-complexes. The consequent podocyte damage may cause cell detachment in urine (Podocyturia-PdoU). PdoU has been assessed in different kidney diseases, but limited data are available in iMN. In this study all patients with a diagnosis of iMN between 15/12/1999-16/07/2014 were tested for PLA2R antibodies (Ab anti-PLA2R, ELISA kit) and PdoU by flow cytometry with anti-podocalyxin antibody. A semi-quantitative PdoU score was defined according to the percentage of podocalyxin positive cells normalized to the total volume of sample and set relative to the urine creatinine measured in the supernatant. PdoU was positive in 17/27 patients (63%; 1+ score in 6/27-22.2%, 2+ in 4/27-14.8%, 3+ in 2/27-7.4%, 4+ in 5/27-18.5%). Only 2/7 patients with complete remission showed a positive PdoU (1+) while all six patients without remission have significant PdoU. PdoU+ was statistically correlated with the absence of remission and Ab anti-PLA2R + (p < 0.05) but PdoU, analysed as a continuous variable, showed a non-linear correlation with proteinuria or PLA2R antibody levels also in the cohort of patients with two available PdoU tests. In conclusion, PdoU could be detected in iMN and seems to be associated with commonly considered markers of disease activity (proteinuria and Ab anti-PLA2R) with a non-linear correlation. Despite data should be confirmed in large and prospective cohorts, according to the podocyte depletion hypothesis PdoU may represent an early marker of immunological activation with potential prognostic utility.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Correlation between Ab anti-PLA2R and proteinuria. Ab anti-PLA2R and proteinuria shows a linear correlation (R2 = 0.6891, p < 0.005).
Figure 2
Figure 2
Correlation between podocyturia (semiquantitative score) and proteinuria values. Podocytura and proteinuria seem to not be linearly correlated (p = NS).
Figure 3
Figure 3
Correlation between podocyturia (semiquantitative score) and Ab anti-PLA2R. As for proteinuria, podocytura and Ab anti-PLA2R seem to not be linearly correlated (p = NS).
Figure 4
Figure 4
Graphical schematization of idiopathic membranous nephropathy in the context of podocyte depletion hypothesis. (1) In the initial stage, Ab anti-PLA2R caused immunocomplexes-deposition and podocyte damage after interaction with their podocyte target; (2) after the initial damage, podocytura and proteinuria both increase; (3) in case of persisting immunological damage, the reduction of podocyte mass progressively leads to end-stage renal disease (ESRD) with podocyturia decrease and, per contrast, further increase in proteinuria. This figure is created with BioRender.com.
Figure 5
Figure 5
PdoU analysis (flow cytometry). (a) isotype negative control (b) podocalyxin positive cells (PDX PE) on the R3-gate.

References

    1. Glassock RJ. The pathogenesis of idiopathic membranous nephropathy: A 50-year Odyssey. Am. J. Kidney Dis. 2010;56:157–167. doi: 10.1053/j.ajkd.2010.01.008. - DOI - PubMed
    1. Jefferson JA, Pippin JW, Shankland SJ. Experimental models of membranous nephropathy. Drug Discov. Today Dis. Model. 2010;7:27–33. doi: 10.1016/j.ddmod.2010.11.001. - DOI - PMC - PubMed
    1. Farquhar MG, et al. gp330 and RAP: The Heymann nephritis antigenic complex. Ann. N. Y. Acad. Sci. 1994;737:96–113. doi: 10.1111/j.1749-6632.1994.tb44304.x. - DOI - PubMed
    1. Cattran DC. Idiopathic membranous glomerulonephritis. Kidney Int. 2001;59:1983–1994. doi: 10.1046/j.1523-1755.2001.0590051983.x. - DOI - PubMed
    1. McGrogan A, Franssen CFM, De Vries CS. The incidence of primary glomerulonephritis worldwide: A systematic review of the literature. Nephrol. Dial. Transplant. 2011;26:414–430. doi: 10.1093/ndt/gfq665. - DOI - PubMed